Technology

OmniRat, OmniMouse and OmniFlic use patented technology, have broad freedom-to-operate and deliver fully human OmniAb antibodies with high affinity, specificity, expression, solubility and stability.

While transgenic mice expressing human antibodies date back to the 1990’s, our scientists were the first to create a rat (OmniRat) expressing a diversified repertoire of antibodies with fully human idiotypes in 2011. In these animals, endogenous expression of rat immunoglobulin genes was inactivated using transient expression of a zinc-finger nucleases in single-cell rat embryos. IgM, IgG, IgE and IgA analyses demonstrated no detectable levels of rat Ig in our homozygous knockout animals. This important breakthrough was featured in the journal Science in July 2009.

OmniRat produces a diverse repertoire of antibodies with human idiotypes and similar immunological characteristics as rat antibodies from wildtype animals. In collaboration with Pfizer scientists, we have demonstrated that OmniRat:

  • Contains functional recombinant immunoglobulin loci.
  • Rearranges functional human Ig genes.
  • Uses genes with similar frequency as humans.
  • Shows normal human CDR3 length.
  • Employs normal B cell development.
  • Has high expression of immunoglobulins.
  • Displays normal hypermutation and affinity maturation.

These data were published in Journal of Immunology and Journal of Immunological Methods in 2013.

OmniMouse was engineered with the same transgenes as OmniRat. Unlike some other transgenic mice on the market and in development, OmniMouse has freedom to operate. OmniMouse expands the epitope coverage of OmniRat and creates the potential for even broader antibody discovery of single antibodies or antibody cocktails.

OmniFlic is a rat with a single common, rearranged VkJk light chain and the same heavy chain transgene as OmniRat. Antibodies from OmniFlic comprise a single germline Vk sequence and can be generated through comprehensive analysis of the heavy chain repertoires without any use of hybridoma technology, see www.omnideep.com.

The generation of therapeutic antibodies is limited by the diversity of antibody platforms. Therefore, combination of several antibody platforms – OmniRat, OmniMouse and OmniFlic - increases the probability of success of antibody discovery, in particular with difficult targets. Ligand continues to develop OmniAb-enhancing technologies, which will be made available to its partners as it becomes available.

Partners

Merck
Pfizer
Celgene
Amgen
Genmab
Janssen
FivePrime
Aptevo Therapeutics
SeattleGenetics
Symphogen
Armo Biosciences
Hanall Pharmaceutical
Gloria Pharmaceuticals
Tizona
ABBA
F-star
Gilead
Ono
AbbVie
BlueBirdBio
Charite
Genentech
Roche
Teneo
Teva

OmniAb is partnered with a range of large and small biopharmaceutical companies globally. For more information, including regarding OmniAb platform access, please E-mail omniab@ligand.com.